Filtra per Last updated date SelectDopoPrimaFrom - To Date Data di conclusione Questa settimana Questo mese Ultima settimana Ultimo mese Category HumanCorporateVeterinaryHerbal Topic MedicinesCOVID-19PharmacovigilanceVaccinesReferralsPaediatricsRare diseasesRegulatory and procedural guidanceClinical trialsAdvanced therapiesData on medicinesCompliance and inspectionsInnovationMedicine shortagesResearch and developmentBiosimilarsSMEAntimicrobial resistanceCorporateGovernanceBrexitQuality of medicinesGeneric and hybrid medicinesEarly accessMedicines for use outside the EUFeesProduct informationScientific adviceMedical devicesMaximum residue limitMpoxBiologicalsScientific guidelinesVeterinary limited marketsCompassionate useCareersMedication errorPRIMEParallel distributionProcurement Diseases area Viral diseasesCancerImmune-system diseasesDiabetesNeurodegenerative diseasesCardiovascular diseasesHIV and AIDS Responsible body CHMP CVMP PRAC Management Board COMP PDCO CMDh HMPC CAT Patient safety information Patient safety Leave this field blank Filter Esito (3827) Sort by Last update date (new to old)Last update date (old to new)A-ZZ-A Leave this field blank Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022 11 Febbraio 2022NewsHumanCOVID-19PharmacovigilanceReferralsVaccines EMA starts safety review of Janus kinase inhibitors for inflammatory disorders 11 Febbraio 2022NewsHumanReferrals PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market 11 Febbraio 2022NewsHumanReferrals Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU 9 Febbraio 2022NewsHumanData on medicines EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents 8 Febbraio 2022NewsHumanCOVID-19Vaccines Public consultation on reflection paper on prophylactic use of antimicrobials in animals 8 Febbraio 2022NewsVeterinaryAntimicrobial resistance A stronger role for EMA 31 Gennaio 2022NewsCorporate New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma 28 Gennaio 2022NewsHumanMedicines COVID-19: EMA recommends conditional marketing authorisation for Paxlovid 28 Gennaio 2022NewsHumanCOVID-19Medicines New EU rules for safe and high-quality medicines for animals become effective 28 Gennaio 2022NewsVeterinaryRegulatory and procedural guidanceMedicines 1 … 49 50 51 52 53 Page 53 of 383 54 55 56 57 … 383
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022 11 Febbraio 2022NewsHumanCOVID-19PharmacovigilanceReferralsVaccines
EMA starts safety review of Janus kinase inhibitors for inflammatory disorders 11 Febbraio 2022NewsHumanReferrals
PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market 11 Febbraio 2022NewsHumanReferrals
Initiation of DARWIN EU® Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU 9 Febbraio 2022NewsHumanData on medicines
EMA evaluating data on booster dose of COVID-19 vaccine Comirnaty in adolescents 8 Febbraio 2022NewsHumanCOVID-19Vaccines
Public consultation on reflection paper on prophylactic use of antimicrobials in animals 8 Febbraio 2022NewsVeterinaryAntimicrobial resistance
New gene therapy treatment for patients with relapsed or refractory large B-cell lymphoma 28 Gennaio 2022NewsHumanMedicines
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid 28 Gennaio 2022NewsHumanCOVID-19Medicines
New EU rules for safe and high-quality medicines for animals become effective 28 Gennaio 2022NewsVeterinaryRegulatory and procedural guidanceMedicines